<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4260A3C6-7987-4CE4-B5B5-1D3D3FA25E4E"><gtr:id>4260A3C6-7987-4CE4-B5B5-1D3D3FA25E4E</gtr:id><gtr:name>European Synchrotron Radiation Facility (ESRF)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/A8967420-49D3-4509-9912-25FB3EC75B74"><gtr:id>A8967420-49D3-4509-9912-25FB3EC75B74</gtr:id><gtr:name>University of Sussex</gtr:name><gtr:department>Sch of Life Sciences</gtr:department><gtr:address><gtr:line1>The Administration</gtr:line1><gtr:line2>Sussex House</gtr:line2><gtr:line3>Falmer</gtr:line3><gtr:line4>Brighton</gtr:line4><gtr:line5>East Sussex</gtr:line5><gtr:postCode>BN1 9RH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A8967420-49D3-4509-9912-25FB3EC75B74"><gtr:id>A8967420-49D3-4509-9912-25FB3EC75B74</gtr:id><gtr:name>University of Sussex</gtr:name><gtr:address><gtr:line1>The Administration</gtr:line1><gtr:line2>Sussex House</gtr:line2><gtr:line3>Falmer</gtr:line3><gtr:line4>Brighton</gtr:line4><gtr:line5>East Sussex</gtr:line5><gtr:postCode>BN1 9RH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4260A3C6-7987-4CE4-B5B5-1D3D3FA25E4E"><gtr:id>4260A3C6-7987-4CE4-B5B5-1D3D3FA25E4E</gtr:id><gtr:name>European Synchrotron Radiation Facility (ESRF)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/7C18E470-F231-4281-A41C-9F5B77E6107E"><gtr:id>7C18E470-F231-4281-A41C-9F5B77E6107E</gtr:id><gtr:firstName>Alison</gtr:firstName><gtr:otherNames>Jane</gtr:otherNames><gtr:surname>Sinclair</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0400735"><gtr:id>EE7FF4DD-9293-424B-84A5-19F934963884</gtr:id><gtr:title>Molecular And Proteomic Analysis Of The Key Epstein-Barr Virus Gene Responsible For Unlocking The Viral Lytic Cycle.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400735</gtr:grantReference><gtr:abstractText>Epstein Barr virus (EBV) is a human virus that causes major clinical problems worldwide including glandular fever, Hodgkin?s Disease and some cancers. Inside the body EBV attempts to hide from our normal defences, although it remains susceptible when replicating. It is possible that cancers that are caused by EBV might be treated by deliberately causing the virus to replicate and thus allowing our normal defence mechanisms to attack the cancer cells.

The proposed project aims to dissect the mechanism of action of a key viral protein that is responsible for starting viral replication. The human genome project revealed that this gene, called BZLF1, is similar to a family of human genes, but it has some important differences. We have so far identified three aspects that are unique to the protein made from BZLF1 (called Zta) and we will explore these unusual features in order to ascertain their mechanisms of action. It is anticipated that this approach will identify novel targets against which therapeutic agents can be developed which will aid the future manipulation of Zta function in vivo</gtr:abstractText><gtr:technicalSummary>Epstein Barr virus (EBV) is a human g-Herpes virus that poses major clinical problems worldwide. EBV-positive tumour cells express a highly restricted set of EBV genes, which helps to protect them from immune surveillance. Activating the viral lytic cycle in EBV-positive tumour cells results in the expression of viral proteins that contain strong CTL epitopes. It is hoped that by deliberately manipulating viral latency in vivo, tumour cells could be ?revealed? to the patient?s immune system and thus cleared. However, in order to generate a battery of reagents that could be used to manipulate the viral lytic cycle in vivo, it is necessary to first understand the mechanism of action of key viral proteins that control the switch between latency and the lytic cycle. 

The EBV gene BZLF1 is specifically associated with the disruption of latency. This is achieved by (i) reprogramming viral and host transcription patterns by directly interacting with specific DNA sequence elements and by (ii) altering the cellular environment and disrupting cell cycle control by interacting with cellular signal transduction molecules and transcription factors. BZLF1 encodes Zta (ZEBRA, BZLF1), which has homology to the bZIP family of transcription factors. This family consists of a transactivation domain, a basic DNA-contact region and a dimerisation domain containing a coil coiled motif. We have recently shown that Zta is an atypical member of the bZIP family: the coiled coil dimerisation interface is weak; the basic region has additional non-DNA binding functions; and a unique region adjacent to the coiled coil (CT region) is required for full function. Here we aim to explore these atypical features in order to ascertain their mechanisms of action. Specifically we aim to define (i) the minimal region of CT required for function and its relationship with the coiled coil and basic regions, (ii) the precise contribution of residues within the basic region of Zta to the non-DNA binding functions of the basic region, and (iii) to identify novel cellular proteins which interact with the bZIP domain of Zta. From this we will gain a clear understanding of the molecular mechanisms by which the atypical basic, coiled coil and CT regions of Zta act to effect lytic cycle activation and to reprogram cell cycle control in infected cells. It is anticipated that this approach will identify novel targets against which therapeutic agents can be developed which will aid the future manipulation of Zta function in vivo.</gtr:technicalSummary><gtr:fund><gtr:end>2008-12-04</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-09-05</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>299998</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Genome Damage and Stability Centre</gtr:department><gtr:description>Structrual analysis of Zta</gtr:description><gtr:id>12BCD44C-C233-4480-8DE8-496FBD8CC8B0</gtr:id><gtr:impact>19656881, 18631132 ,18369464</gtr:impact><gtr:partnerContribution>Collaboration and joint publicationJoint publication and collaboration on Wellcome Trust grant for further research</gtr:partnerContribution><gtr:piContribution>both collaborators aided us with our research project</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Synchrotron Radiation Facility (ESRF)</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:description>Structrual analysis of Zta</gtr:description><gtr:id>51FBE84E-8CBF-421F-8FB9-B28ED104C930</gtr:id><gtr:impact>19656881, 18631132 ,18369464</gtr:impact><gtr:partnerContribution>Collaboration and joint publicationJoint publication and collaboration on Wellcome Trust grant for further research</gtr:partnerContribution><gtr:piContribution>both collaborators aided us with our research project</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>oral presentations</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6C8A6637-51A8-43A6-AC48-8FF338B5A62A</gtr:id><gtr:impact>2008 20 minute presentation at International EBV conference 15 minute presentation at International Herpesvirus workshop 15 minute presentation at Biochemistry Society focus meeting 15 minute presntation at Soceity for General microbiology meeting 2007 15 minute presentation at Soceity for General microbiology meeting Seminar at London School of Hygiene and Tropical Medicine, London. Seminar at Institute of Animal Health, Compton. 15minute presenation at European EBV meeting in Heidelberg Brighton Science festival - meet the scientist session

n/a</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>281251</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Project Grant (Functional interplay between Epstein-Barr virus and the 53BP1/ATM DNA damage response pathway during viral replication.)</gtr:description><gtr:end>2011-11-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>855C866A-9F1E-43A0-93FB-B8BEF0019790</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F42AC38B-477F-47FB-8EBF-936052C9BFA7"><gtr:id>F42AC38B-477F-47FB-8EBF-936052C9BFA7</gtr:id><gtr:title>The reversal of epigenetic silencing of the EBV genome is regulated by viral bZIP protein.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/160ff18b886f49fb0cd06e1b97cc994c"><gtr:id>160ff18b886f49fb0cd06e1b97cc994c</gtr:id><gtr:otherNames>Karlsson QH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B56F5127-3162-4F5E-90C6-09A7F0E4671E"><gtr:id>B56F5127-3162-4F5E-90C6-09A7F0E4671E</gtr:id><gtr:title>Evaluation of a prediction protocol to identify potential targets of epigenetic reprogramming by the cancer associated Epstein Barr virus.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ac776f9f442ad3cca2438e5af1c2fc8a"><gtr:id>ac776f9f442ad3cca2438e5af1c2fc8a</gtr:id><gtr:otherNames>Flower K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/35FA7D79-080F-4BB4-8B7F-2901C1538DBC"><gtr:id>35FA7D79-080F-4BB4-8B7F-2901C1538DBC</gtr:id><gtr:title>The Epstein-Barr virus lytic cycle activator Zta interacts with methylated ZRE in the promoter of host target gene egr1.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8674fb2aa9100479a18fde88da29723a"><gtr:id>8674fb2aa9100479a18fde88da29723a</gtr:id><gtr:otherNames>Heather J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/61AE61D6-B12F-4D5A-9D03-0F07C922319E"><gtr:id>61AE61D6-B12F-4D5A-9D03-0F07C922319E</gtr:id><gtr:title>Atypical bZIP domain of viral transcription factor contributes to stability of dimer formation and transcriptional function.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/56620cfd2180dbcc3618dabec964d6d6"><gtr:id>56620cfd2180dbcc3618dabec964d6d6</gtr:id><gtr:otherNames>Schelcher C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/033317E6-1CAE-457E-BDC2-7DCB6B7A5D44"><gtr:id>033317E6-1CAE-457E-BDC2-7DCB6B7A5D44</gtr:id><gtr:title>Methylated DNA recognition during the reversal of epigenetic silencing is regulated by cysteine and serine residues in the Epstein-Barr virus lytic switch protein.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/160ff18b886f49fb0cd06e1b97cc994c"><gtr:id>160ff18b886f49fb0cd06e1b97cc994c</gtr:id><gtr:otherNames>Karlsson QH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/211E3FCD-1D28-451E-A380-810583EB7876"><gtr:id>211E3FCD-1D28-451E-A380-810583EB7876</gtr:id><gtr:title>Functional interaction between Epstein-Barr virus replication protein Zta and host DNA damage response protein 53BP1.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a02d6fb19d020c3a8c6254c6e37c9dea"><gtr:id>a02d6fb19d020c3a8c6254c6e37c9dea</gtr:id><gtr:otherNames>Bailey SG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400735</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>